Cited by 687HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Open access

Wheeler, Deric L., Dunn, Emily F., Harari, Paul M.·2010·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2010.97PMC PMC2929287

Open this paper in CoChat — free account

Abstract

EGFR is a tyrosine kinase that participates in the regulation of cellular homeostasis. Following ligand binding, EGFR stimulates downstream cell signaling cascades that influence cell proliferation, apoptosis, migration, survival and complex processes, including angiogenesis and tumorigenesis. EGFR has been strongly implicated in the biology of human epithelial malignancies, with therapeutic applications in cancers of the colon, head and neck, lung, and pancreas. Accordingly, targeting EGFR has been intensely pursued, with the development of a series of promising molecular inhibitors for use in clinical oncology. As is common in cancer therapy, challenges with respect to treatment resistance emerge over time. This situation is certainly true of EGFR inhibitor therapies, where intrinsic and acquired resistance is now well recognized. In this Review, we provide a brief overview regarding the biology of EGFR, preclinical and clinical development of EGFR inhibitors, and molecular mechanisms that underlie the development of treatment resistance. A greater understanding of the mechanisms that lead to EGFR resistance may provide valuable insights to help design new strategies that will enhance the impact of this promising class of inhibitors for the treatment of cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2010.97

Cites

182 of 182 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R. K., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,109
Self-citation
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877

Show all 182 references

Sorted by citations

The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H. Y., Fabbri, M., & Călin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,489
The quest to overcome resistance to EGFR-targeted therapies in cancer
Chong, C. R., & Janne, P. A. (2013) · Nature Medicine · doi:10.1038/nm.3388 · Cited by 1,076
Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors
Sabbah, D. A., Hajjo, R., & Sweidan, K. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200303123102 · Cited by 615
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: Outside-in signaling and relationship to tumor progression
Bauvois, B. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.001 · Cited by 560
Utilizing the folate receptor for active targeting of cancer nanotherapeutics
Zwicke, G. L., Ali Mansoori, G., & Jeffery, C. J. (2012) · Nano Reviews · doi:10.3402/nano.v3i0.18496 · Cited by 458
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N. C., Pedersen, M. W., & Johns, T. G. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3559 · Cited by 464
An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
Guo, D., Reinitz, F., Youssef, M., Hong, C., Nathanson, D., Akhavan, D., Kuga, D., Amzajerdi, A. N., Soto, H., Zhu, S., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0102 · Cited by 452
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 465
Gelatin carriers for drug and cell delivery in tissue engineering
Santoro, M., Tatara, A. M., & Mikos, A. G. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.014 · Cited by 399
An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition
Seguin, L., Kato, S., Franovic, A., Camargo, M. F., Lesperance, J., Elliott, K. C., Yebra, M., Mielgo, A., Lowy, A. M., Husain, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2953 · Cited by 374
Personalised cancer medicine
Jackson, S. E., & Chester, J. D. (2014) · International Journal of Cancer · doi:10.1002/ijc.28940 · Cited by 383
Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
Duffy, M. J., Lamerz, R., Haglund, C. H., Nicolini, A., Kalousová, M., Holubec, L., & Sturgeon, C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28384 · Cited by 365
The role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. G. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 341
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325
“in EGFR, KRAS, BRAF, and PIK3CA, and loss or inactivation of PTEN (10, 11).”
Background
Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system
Zou, K., Zhao, L., Zhang, Y., Zhang, H.-Y., Li, B., Zhu, W., Shi, J., Jia, Q., & Li, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.125 · Cited by 317
MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells
Hwang, W., Jiang, J., Yang, S.-H., Huang, T. S., Lan, H., Teng, H., Yang, C.-Y., Tsai, Y., Lin, C.-H., Wang, H., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb2910 · Cited by 306
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology
Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3342 · Cited by 288
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, W. S., Goldberg, R. M., Lenz, H., Shields, A. F., Gibney, G. T., Tan, A. R., Brown, J., Eisenberg, B., Heath, E. I., Phuphanich, S., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21560 · Cited by 264
The Role of Inflammation in Lung Cancer
Gomes, M. P., Teixeira, A. L., Coelho, A., Araújo, A., & Medeiros, R. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_1 · Cited by 257
Molecular pathology of lung cancer: key to personalized medicine
Liang Cheng, C., Alexander, R. E., MacLennan, G. T., Cummings, O. W., Montironi, R., Antonio Lopez-beltran, B., Cramer, H. M., Davidson, D. D., & Zhang, S. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.215 · Cited by 249
Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations
Han, W., & Lo, H. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.011 · Cited by 245
Nuclear EGFR as a Molecular Target in Cancer
Brand, T. M., Iida, M., Luthar, N., Starr, M. M., Huppert, E. J., & Wheeler, D. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.010 · Cited by 238
Self-citation
The Spectrum of Achalasia: Lessons From Studies of Pathophysiology and High-Resolution Manometry
Kahrilas, P. J., & Boeckxstaens, G. E. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.08.038 · Cited by 236
Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: Novel anti‐tumor mechanisms of Cannabidiol in breast cancer
Elbaz, M., Nasser, M. W., Ravi, J., Wani, N. A., Ahirwar, D. K., Zhao, H., Oghumu, S., Satoskar, A. R., Shilo, K., Carson, W. E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2014.12.010 · Cited by 233
Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
Young, A., Lou, D., & McCormick, F. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0231 · Cited by 211
Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression
Farina, A. R., & Mackay, A. R. (2014) · Cancers · doi:10.3390/cancers6010240 · Cited by 215
Cutaneous Squamous Cell Carcinoma: From Biology to Therapy
Corchado‐Cobos, R., García‐Sancha, N., González‐Sarmiento, R., Pérez‐Losada, J., & Cañueto, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082956 · Cited by 225
The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells
Cai, W.-Q., Zeng, L.-S., Wang, L., Wang, Y., Cheng, J.-T., Zhang, Y., Han, Z.-W., Zhou, Y., Huang, S.-L., Wang, X.-W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01249 · Cited by 208
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer
Byeon, H. K., Ku, M., & Yang, J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0202-2 · Cited by 199
Oncogenes in Cell Survival and Cell DeathPreprint
Shortt, J., & Johnstone, R. W. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009829 · Cited by 200
Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
Chew, H. Y., de Lima, P. O., Cruz, J. L. G., Banushi, B., Echejoh, G. O., Hu, L., Joseph, S. R., Lum, B., Rae, J., O’Donnell, J. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.019 · Cited by 186
circRNA-miRNA-mRNA regulatory network in human lung cancer: an update
Liang, Z., Guo, C., Zou, M., Meng, P., & Zhang, T.-T. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01245-4 · Cited by 190
The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis
Berasain, C., & Avila, M. A. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0907-x · Cited by 175
Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation
Toulany, M., & Rodemann, H. P. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.07.003 · Cited by 174
Slug Confers Resistance to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
Chang, T., Tsai, M.-F., Su, K., Wu, S.-G., Huang, C.-P., Yu, S., Yu, Y., Lan, C., Yang, C.-H., Lin, S.-B., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1440oc · Cited by 162
Head and neck cancer: from anatomy to biology
Bose, P., Brockton, N. T., & Dort, J. C. (2013) · International Journal of Cancer · doi:10.1002/ijc.28112 · Cited by 166
Managing drug resistance in cancer: lessons from HIV therapy
Bock, C., & Lengauer, T. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3297 · Cited by 160
The Gastrointestinal Tumor Microenvironment
Quante, M., Varga, J., Wang, T. C., & Greten, F. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.03.052 · Cited by 154
Cannabinoid Receptors, CB1 and CB2, as Novel Targets for Inhibition of Non–Small Cell Lung Cancer Growth and Metastasis
Preet, A., Qamri, Z., Nasser, M. W., Prasad, A., Shilo, K., Zou, X., Groopman, J. E., & Ganju, R. K. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0181 · Cited by 156
Gelatin as It Is: History and Modernity
Mikhailov, O. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043583 · Cited by 159
Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay
Schwaederle, M. C., Husain, H., Fanta, P. T., Piccioni, D. E., Kesari, S., Schwab, R. B., Banks, K. C., Lanman, R. B., Talasaz, A. H., Parker, B. A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7110 · Cited by 151
Affibody‐Functionalized Gold–Silica Nanoparticles for Raman Molecular Imaging of the Epidermal Growth Factor Receptor
Jokerst, J. V., Miao, Z., Zavaleta, C. L., Cheng, Z., & Gambhir, S. S. (2011) · Small · doi:10.1002/smll.201002291 · Cited by 146
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
Chell, V., Balmanno, K., Little, A. S., Wilson, M. I., Andrews, S., Blockley, L., Hampson, M., Gavine, P. R., & Cook, S. J. (2012) · Oncogene · doi:10.1038/onc.2012.319 · Cited by 146
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
Pozo, N., Zahonero, C., Fernández, P., Liñares, J. M., Ayuso‐Sacido, Á., Hagiwara, M., Pérez‐Núñez, Á., Ricoy, J. R., Hernández‐Laín, A., Sepúlveda-Sánchez, J. M., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci63623 · Cited by 139
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT
Bruzzese, F., Leone, A., Rocco, M., Carbone, C., Piro, G., Caraglia, M., Gennaro, E. D., & Budillon, A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22574 · Cited by 142
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC)
Cohen, R. B. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.002 · Cited by 135
Targeting the Adaptability of Heterogeneous Aneuploids
Chen, G., Mulla, W. A., Kucharavy, A., Tsai, H.-J., RUBINSTEIN, B. Y., Conkright, J. J., McCroskey, S., Bradford, W. D., Weems, L., Haug, J. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.026 · Cited by 135
Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells
Park, J.-J., Yi, J. Y., Jin, Y. B., Lee, Y.-J., Lee, J., Lee, Y., Ko, Y., & Lee, M. Y. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.007 · Cited by 129
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study
Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 130
Inhibition of Oncogenic Epidermal Growth Factor Receptor Kinase Triggers Release of Exosome-like Extracellular Vesicles and Impacts Their Phosphoprotein and DNA Content*
Montermini, L., Meehan, B., Garnier, D., Lee, W.-J., Lee, T., Guha, A., Al-Nedawi, K., & Rak, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679217 · Cited by 121
Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma
Cornellà, H., Alsinet, C., Sayols, S., Zhang, Z., Hao, K., Cabellos, L., Hoshida, Y., Villanueva, A., Thung, S. N., Ward, S. C., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.028 · Cited by 128
EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment
Keller, S., & Schmidt, M. H. H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061295 · Cited by 130
Proteomic Identification of Cysteine Cathepsin Substrates Shed from the Surface of Cancer Cells
Sobotič, B., Vizovišek, M., Vidmar, R., Damme, P. V., Gocheva, V., Joyce, J. A., Gevaert, K., Türk, V., Turk, B., & Fonovič, M. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044628 · Cited by 123
Increasing the α 2, 6 Sialylation of Glycoproteins May Contribute to Metastatic Spread and Therapeutic Resistance in Colorectal Cancer
Park, J.-J., & Lee, M. (2013) · Gut and Liver · doi:10.5009/gnl.2013.7.6.629 · Cited by 121
Potential mechanisms of CD133 in cancer stem cells
Jang, J.-W., Song, Y., Kim, S.-H., Kim, J., & Seo, H. R. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.07.008 · Cited by 124
HDAC6 promotes cell proliferation and confers resistance to temozolomide in glioblastoma
Wang, Z., Hu, P., Tang, F., Lian, H., Chen, X., Zhang, Y., He, X., Liu, W., & Xie, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.001 · Cited by 119
Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer
Roh, J., Kim, E. H., Park, J. Y., Kim, J. W., Kwon, M., & Lee, B.-H. (2014) · Oncotarget · doi:10.18632/oncotarget.2402 · Cited by 118
In search of the Holy Grail: Folate-targeted nanoparticles for cancer therapy
Garcia‐Bennett, A. E., Nees, M., & Fadeel, B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.01.023 · Cited by 118
Emerging Role of mTOR in the Response to Cancer Therapeutics
Ilagan, E., & Manning, B. D. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.03.008 · Cited by 118
p53 Modulates Acquired Resistance to EGFR Inhibitors and Radiation
Huang, S., Benavente, S., Armstrong, E. A., Li, C., Wheeler, D. L., & Harari, P. M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0128 · Cited by 116
Self-citation
Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer
Li, Q., Zhang, D., Chen, X., He, L., Li, T., Xu, X., & Li, M. (2015) · Scientific Reports · doi:10.1038/srep16082 · Cited by 114
Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 122
Delphinidin Reduces Cell Proliferation and Induces Apoptosis of Non-Small-Cell Lung Cancer Cells by Targeting EGFR/VEGFR2 Signaling Pathways
Pal, H. C., Sharma, S., Strickland, L. R., Agarwal, J., Athar, M., Elmets, C. A., & Afaq, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077270 · Cited by 111
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
Bora-Singhal, N., Perumal, D., Nguyen, J. V., & Chellappan, S. (2015) · Neoplasia · doi:10.1016/j.neo.2015.07.001 · Cited by 110
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
Boeck, S. H., Jung, A., Laubender, R. P., Neumann, J. H. L., Egg, R., Goritschan, C., Vehling‐Kaiser, U., Winkelmann, C., von Weikersthal, L. F., Clemens, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.495 · Cited by 107
Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation
Endo, H., Okami, J., Okuyama, H., Kumagai, T., Uchida, J., Kondo, J., Takehara, T., Nishizawa, Y., Imamura, F., Higashiyama, M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779ccf · Cited by 109
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124
Gao, Y., Fan, X., Li, W., Wei, P., Deng, Y. L., & Fu, X. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.02.073 · Cited by 107
EGF induces epithelial-mesenchymal transition and cancer stem-like cell properties in human oral cancer cells via promoting Warburg effect
Xu, Q., Zhang, Q., Ishida, Y., Hajjar, S., Tang, X., Shi, H., Dang, C. V., & Le, A. D. (2016) · Oncotarget · doi:10.18632/oncotarget.13771 · Cited by 107
mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations
Wang, Z., Martı́n, D., Molinolo, A., Patel, V., Iglesias‐Bartolomé, R., Degese, M. S., Vitale-Cross, L. A., Chen, Q., & Gutkind, J. S. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju215 · Cited by 106
A novel STAT3 inhibitor W2014-S regresses human non-small cell lung cancer xenografts and sensitizes EGFR-TKI acquired resistance
Zheng, Q., Dong, H., Mo, J., Zhang, Y., Huang, J., Ouyang, S., Shi, S., Zhu, K., Qu, X., Hu, W., et al. (2020) · Theranostics · doi:10.7150/thno.49600 · Cited by 106
Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models
Rosa, R., Marciano, R., Malapelle, U., Formisano, L., Nappi, L., D’Amato, C., D'Amato, V., Damiano, V., Marfè, G., Vecchio, S. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1050 · Cited by 104
Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment
van der Meel, R., Oliveira, S., Altıntaş, I., Haselberg, R., van der Veeken, J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Storm, G., Hennink, W. E., Schiffelers, R. M., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.027 · Cited by 105
Quercetin suppresses lung cancer growth by targeting Aurora B kinase
Xingyu, Z., Peijie, M., Peng, D., Youg, W., Daojun, W., Chen, X., Xijun, Z., & Yangrong, S. (2016) · Cancer Medicine · doi:10.1002/cam4.891 · Cited by 100
Discovery of N-((3 R,4 R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1 H-pyrazol-4-yl)amino)-9-methyl-9 H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR
Planken, S., Behenna, D. C., Nair, S. K., Johnson, T. O., Nagata, A., Almaden, C., Bailey, S., Ballard, T. E., Bernier, L., Cheng, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01894 · Cited by 97
Targeting Epidermal Growth Factor Receptor in Head and Neck Cancer
Bhatia, A. K. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000623 · Cited by 96
STAT3 Mediates Resistance to MEK Inhibitor through MicroRNA miR-17
Dai, B., Meng, J., Peyton, M., Girard, L., Bornmann, W. G., Ji, L., Minna, J. D., Fang, B., & Roth, J. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3647 · Cited by 94
Mechanistic insights into the activation of oncogenic forms of EGF receptor
Wang, Z., Longo, P. A., Tarrant, M. K., Kim, K., Head, S. A., Leahy, D. J., & Cole, P. A. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2168 · Cited by 94
TRPC1 Protein Channel Is Major Regulator of Epidermal Growth Factor Receptor Signaling
Tajeddine, N., & Gailly, P. L. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340034 · Cited by 93
Cancer stem‐like cell properties are regulated by EGFR / AKT /β–catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma
Ma, L., Zhang, G., Miao, X., Deng, X., Wu, Y., Liu, Y., Jin, Z., Li, X., Liu, Q., Sun, D., et al. (2013) · FEBS Journal · doi:10.1111/febs.12226 · Cited by 92
Simultaneous β1 integrin-EGFR Targeting and Radiosensitization of Human Head and Neck Cancer
Eke, I., Zscheppang, K., Dickreuter, E., Hickmann, L., Mazzeo, E., Unger, K., Krause, M., & Cordes, N. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju419 · Cited by 95
Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Madoz‐Gúrpide, J., Zazo, S., Chamizo, C., Casado, V., Caramés, C., Gavín, E., Cristóbal, I., García‐Foncillas, J., & Rojo, F. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0633-7 · Cited by 91
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
Sohal, D. P. S., Mykulowycz, K., Uehara, T., Teitelbaum, U. R., Damjanov, N., Giantonio, B. J., Carberry, M., Wissel, P. S., Jacobs-Small, M., O'Dwyer, P. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt416 · Cited by 90
Regulation of Epidermal Growth Factor Receptor Signaling and Erlotinib Sensitivity in Head and Neck Cancer Cells by miR-7
Kalinowski, F. C., Giles, K. M., Candy, P. A., Alishum, A., Ganda, C., Epis, M. R., Webster, R. J., & Leedman, P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047067 · Cited by 89
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma
Tagliaferri, P., Rossi, M., Martino, M. T. D., Amodio, N., Leone, E., Gullà, A., Neri, A., & Tassone, P. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912802429355 · Cited by 89
Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition
Boesch, M., Spizzo, G., & Seeber, A. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.17-0289 · Cited by 88
EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation
Minder, P., Zając, E., Quigley, J. P., & Deryugina, E. I. (2015) · Neoplasia · doi:10.1016/j.neo.2015.08.002 · Cited by 87
Yes and Lyn play a role in nuclear translocation of the Epidermal Growth Factor Receptor
Iida, M., Brand, T. M., Campbell, D., Li, C.-R., & Wheeler, D. (2012) · Oncogene · doi:10.1038/onc.2012.90 · Cited by 84
Self-citation
Unexpected Off-Targets and Paradoxical Pathway Activation by Kinase Inhibitors
Hantschel, O. D. (2014) · ACS Chemical Biology · doi:10.1021/cb500886n · Cited by 87
Epidermal growth factor receptor inhibits colitis-associated cancer in mice
Dubé, P. E., Yan, F., Punit, S., Girish, N., McElroy, S. J., Washington, M. K., & Polk, D. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62888 · Cited by 86
EGFR/JIP-4/JNK2 Signaling Attenuates Cetuximab-Mediated Radiosensitization of Squamous Cell Carcinoma Cells
Eke, I., Schneider, L., Förster, C., Zips, D., Kunz‐Schughart, L. A., & Cordes, N. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2021 · Cited by 90
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Ma, Y., Tang, N., Thompson, R. C., Mobley, B. C., Clark, S. W., Sarkaria, J. N., & Wang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1677 · Cited by 84
Berberine Inhibits Proliferation and Down-Regulates Epidermal Growth Factor Receptor through Activation of Cbl in Colon Tumor Cells
Wang, L., Cao, H., Lü, N., Liu, L., Wang, B., Hu, T., Israel, D. A., Peek, R. M., Polk, D. B., & Yan, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056666 · Cited by 82
Antibodies directed against receptor tyrosine kinases
Fauvel, B., & Yasri, A. (2014) · mAbs · doi:10.4161/mabs.29089 · Cited by 81
RasGRP1 opposes proliferative EGFR–SOS1–Ras signals and restricts intestinal epithelial cell growth
Depeille, P., Henricks, L. M., van de Ven, R. A. H., Lemmens, E., Wang, C.-Y., Matli, M., Werb, Z., Haigis, K. M., Donner, D., Warren, R., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3175 · Cited by 80
Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab
Wadlow, R. C., Hezel, A. F., Abrams, T. A., Blaszkowsky, L. S., Fuchs, C. S., Kulke, M. H., Kwak, E. L., Meyerhardt, J. A., Ryan, D. P., Szymonifka, J. D., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0452 · Cited by 81
The proto-oncogene KRAS is targeted by miR-200c
Kopp, F. B., Wagner, E., & Roidl, A. (2013) · Oncotarget · doi:10.18632/oncotarget.1427 · Cited by 79
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
Braig, F., Kriegs, M., Voigtlaender, M., Habel, B., Grob, T. J., Biskup, K., Blanchard, V., Sack, M., Thalhammer, A., Batalla, I. B., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0754 · Cited by 81

Authors: Wheeler, D. L., Dunn, E. F., & Harari, P. M.
Affiliations: University of Wisconsin–Madison (US)
Corresponding author: Wheeler, Deric L.
ORCID: Wheeler, Deric L.
Dunn, Emily F.
Harari, Paul M.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2010-06-15
Volume: 7
Issue: 9
Pages: 493-507
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2010.97
PMC: PMC2929287
OpenAlex: W2053439872
Cited by: 683
References: 182
Citations by year: 2026: 21 · 2025: 20 · 2024: 35 · 2023: 29 · 2022: 31 · 2021: 29 · 2020: 44 · 2019: 25 · 2018: 36 · 2017: 50 · 2016: 46 · 2015: 61 · 2014: 66 · 2013: 68 · 2012: 64
FWCI: 6.61
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5t32ca009614-25)
U.S. Public Health Service (P30CAO14520)
National Cancer Institute (T-32 CA 0096-14, R01CA113448)
National Center for Research Resources (UL1RR025011)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords: EGFR inhibitors, EGFR, acquired drug resistance, intrinsic resistance, tyrosine kinase inhibitors, resistance mechanisms, EGFR signaling, epithelial malignancies, lung cancer, head and neck cancer, colon cancer, pancreatic cancer, combination therapy
MeSH terms: Cetuximab, Erlotinib Hydrochloride, Gefitinib, Panitumumab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Proto-Oncogene Proteins, Quinazolines, Proto-Oncogene Proteins p21(ras), Treatment Outcome, Disease Progression, ras Proteins, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Antibodies, Monoclonal, Humanized, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks